BioGaia (STO:BIOG) has signed two different agreements for its oral health products, one with Pharmaforte for the Singapore Republic and one with Dexcel Pharma for Israel. Recently, a double-blind, placebo-controlled, randomised study in 20 patients with periodontitis was published. The results showed that pocket depth, the most important disease indicator, was significantly reduced in the patients supplemented by the probiotic Lactobacillus reuteri Prodentis compared to the placebo group.
Both agreements are exclusive and refer to the sales of BioGaia’s oral health products. In both countries the products will be sold under the BioGaia brand and launches are planned to take place during 2013. BioGaia’s oral health products contain the patented and well-studied probiotic Lactobacillus reuteri Prodentis. Today BioGaia's oral health products are sold in more than 20 countries worldwide.
A study in chronic periodontal patients, conducted completely independently of BioGaia, was published online Nov. 26, 2012, in Acta Odontologica Scandinavia. All parameters tested in the study, plaque index, bleeding on probing and pocket depths, were significantly reduced after 30 days of intervention with Lactobacillus reuteri Prodentis. As no professional cleaning was performed during or before the intervention period the results refers only to the supplementation of Lactobacillus reuteri Prodentis. The patients in the placebo group did not show any significant changes in any of the parameters.
These significant effects of Lactobacillus reuteri Prodentis confirm earlier published data with Lactobacillus reuteri Prodentis.
“It is encouraging to see that our efforts within the oral health area are showing results, as we are now continuing the global roll-out of our oral health products. By collaborating with strong local partners for each market, we can unleash the full commercial potential of BioGaia ProDentis. When at the same time the proof for clinically relevant effects with Lactobacillus reuteri Prodentis is growing. I am confident that this product segment could become one of our most important areas”, says Peter Rothschild, CEO of BioGaia.
Pharmaforte is one of the leading pharmaceutical distribution companies in Singapore and manages a portfolio of healthcare brands as well as licensed products from biotech firms and multinational companies. The company will promote BioGaia ProDentis to pharmacies, hospitals and dental clinics.
Dexcel Pharma is the second largest Israeli pharmaceutical manufacturer with more than 40 years of experience in the domestic market. The company will promote BioGaia ProDentis both towards dental health care professionals as well as the public.